drugset / Trial / NCT06316843
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19.
Timeline
- Start
- 2023-10-15
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 200 mg | — |
| Subject | Valacyclovir | Unknown | 750 mg | — |
| Subject | Valacyclovir | Unknown | 1500 mg | — |